CoChat

Facilitating Clinical Implementation of Pharmacogenomics

Open access
Mrazek, David A., Lerman, Caryn · 2011 · JAMA
Cited by 64

The DOI matches its Crossref record.

Abstract

Variability in drug response can be explained, in part, by genetic differences among patients.A clear role in drug toxicity and efficacy has been established for some gene-drug combinations, yet implementation of pharmacogenomic tests in clinical practice lags behind this knowledge.The evidence-adoption gap for many pharmacogenomic tests can be addressed in the short term through the development of consensus-based practice guidelines and clinician education.For genetic variants associated with severe drug toxicities, there is a strong impetus for adoption.An example is the HLA-B*15:02 variant, associated with the potentially lethal Stevens-Johnson syndrome in Asian patients treated with carbamazepine. 1 Another example is the poor metabolizers of cytochrome p450 2D6 substrates that represent a range of risk when exposed to specific medications.The death of a child treated with fluoxetine illustrates the importance of identifying patients with impaired metabolism as well as the ethical dilemma of knowingly exposing patients with minimal metabolic capacity to substrates that require a specific enzyme for clearance.2 The adoption of testing for genetic variants that have a more modest effect on drug response or risk of adverse events has been more variable.In oncology, somatic mutation or expression tests for specific drug targets in tumors (eg, EGFR, ERBB2) can provide a clear indication for treatment efficacy, and rates of adoption have been relatively high.However, the current evidence for other pharmacogenomic tests for efficacy determination is less clear.For example, patients of European ancestry who carry the higher-activity allele of a serotonin transporter gene variant have a modest increased probability of responding to serotonin reuptake inhibitors.3 The decision to use testing to increase the probability of a good response must be weighed against other issues, such as the efficacy and cost of ©2011 American Medical Association.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2011.1010

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 64

Metadata

Authors
Mrazek, D. A., & Lerman, C.
Venue
JAMA
Published
2011-07-20
Volume
306
Issue
3
Pages
304-5
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2063395862
Cited by
64
References
0
FWCI
10.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Facilitating Clinical Implementation of Pharmacogenomics. https://app.cochat.ai/papers/10.1001/jama.2011.1010
The paper
Mrazek, D. A., & Lerman, C. (2011). Facilitating Clinical Implementation of Pharmacogenomics. JAMA. https://doi.org/10.1001/jama.2011.1010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.